Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Ambulance risk score could speed heart attack care

NCT ID NCT07252245

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 11, 2026 · Updated 3 times

Summary

This trial tests whether using a risk score and a rapid blood test in the ambulance can help decide where to take patients with chest pain. About 1,048 adults at intermediate or high risk for a heart attack will be randomly assigned to either this new triage method or usual care. The goal is to see if the new approach is faster, cheaper, and just as safe.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this approach could speed up diagnosis and treatment for heart attack patients, reduce hospital stays, and save healthcare costs.
What could go wrong
This is an early-stage trial testing a new triage process, not a treatment. It may not show clear benefits or could be difficult to implement widely.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 1,048 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2026

Expected to finish

Feb 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * All out-of-hospital patients with chest pain or symptoms suggestive of ACS with an indication for transfer to the (cardiac) emergency department to evaluate and rule out ACS * Modified HEAR(T) score ≥ 4 * The patient has been informed of the nature of the study, agrees to its provisions and has provided written informed consent. Exclusion Criteria: * Electrocardiographic ST-segment elevation (STEMI) * Patients with confirmed myocardial infarction, PCI or CABG \<14 days prior to inclu-sion * Patients presenting an obvious non-cardiac cause for the chest complaints who need evaluation at an emergency department, e.g. trauma, pneumothorax, sepsis, etc. * Patients in comatose state, defined as an EMV \<8 * Patients with known cognitive impairment * Pregnancy * Patients presenting with cardiogenic shock, defined as: systolic blood pressure \<90mmHg and heart rate \>100 and peripheral oxygen saturation \<90% (without oxygen administration) * Patients presenting with syncope * Patients presenting with signs of heart failure * Patients presenting with second or third degree atrioventricular block * Patients without known supraventricular tachycardia i.e. unknown atrial fibrillation (known atrial fibrillation with adequate rate control can be included) * Patients with known end-stage renal disease (dialysis and/or GFR \< 30 ml/min) * Patients without a pre-hospital 12-lead ECG performed or available * Patients suspicious of aortic dissection or pulmonary embolism * Communication issues with patient/language barrier * Any significant medical or mental condition, which in the Investigator's opinion may interfere with the patient's optimal participation in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non ST segment elevation acute coronary syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    3 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • RAV Brabant midden-west-noord: post Haps

    RECRUITING

    Haps, Netherlands

    Contact Email: •••••@•••••

  • Radboudumc Nijmegen, The Netherlands

    RECRUITING

    Nijmegen, 6525 GA, Netherlands

  • Veiligheidsregio Gelderland-Zuid

    NOT_YET_RECRUITING

    Nijmegen, Netherlands

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.